search
Back to results

Sitagliptin Therapy and Kinetics of Inflammatory Markers

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Sitagliptin
Placebo
Sponsored by
Laval University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring sitagliptin, diabetes, inflammation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males 18 to 65 years of age.
  • Post-menopausal women under age 65 on stable medical therapy for 6 months before the study (the patient should have demonstrated stable lipid panels)
  • Women should not be on hormone replacement therapy (no recent starting or stopping)
  • Type 2 diabetes as defined by the American Diabetes Association.
  • Non-smoker.
  • Body mass index between 25.0 and 40.0 kg/m2.
  • Baseline glycated hemoglobin A1c (HbA1c) between 6.5 and 8.5%.
  • Baseline fasting plasma glucose < 15.0 mmol/L.
  • Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at screening and week -4.
  • Patients having received stable doses of metformin for at least 3 months before randomization.
  • Subjects must be willing to give written informed consent and able to adhere to dosing schedule, visit schedule and phone follow-up assessment.
  • Patients should be otherwise generally healthy, without elevations in hepatic transaminases or abnormal renal function or coagulation.
  • Patients having normal thyroid stimulating hormone at screening

Exclusion Criteria:

  • Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded.
  • Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic complications will be excluded.
  • Patients having received or being treated with insulin or a thiazolidinedione within the past 6 months will be excluded.
  • Patients taking any other hypoglycemic agent, other than metformin.
  • Subjects will be excluded if they have cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, significant alcohol intake etc.).
  • Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • Individuals with a history of mental instability, drug or alcohol abuse or individuals who have been treated or are being treated for severe psychiatric illness that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • History of alcohol or drug abuse within the past 2 years. Patients must not take alcohol during the study.
  • Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease, that would limit study evaluation or participation.
  • Known impairment of renal function (serum creatinine levels > 1.7 mg/dL for men), dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3 ± 1 g).
  • Active or chronic hepatobiliary or hepatic disease. In addition, patients with aspartate aminotransferase or alanine aminotransferase >2 x upper limit of the laboratory reference range will be excluded.
  • Subjects with coagulopathy (prothrombin time or partial thromboplastin time at Visit 1 >1.5 times control).
  • Subjects with hemoglobin >2 x the lower limit of the laboratory reference range will be excluded.
  • Patients who are known to have tested positive for human immunodeficiency virus (HIV).
  • Patients who are currently enrolled in another clinical study.
  • Patients who have used any investigational drug within 30 days of the first clinic visit.
  • Congestive heart failure New York Heart Association (NYHA) Class III or IV. Uncontrolled cardiac arrhythmias within 3 months of study entry.
  • Uncontrolled diabetes mellitus (HbA1c>8.5%) or other endocrine or metabolic disease known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on replacement doses of thyroid hormone are eligible for enrollment.

Sites / Locations

  • Laval University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Sitagliptin first, then Placebo

Placebo first, then Sitagliptin

Arm Description

Sitagliptin 100 mg/d for 6 weeks Wash-out 14 days Placebo for 6 weeks

Placebo for 6 weeks Wash-out 14 days Sitagliptin 100 mg/d for 6 weeks

Outcomes

Primary Outcome Measures

Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period

Secondary Outcome Measures

Measurement of Serum Amyloid A Production Rate With Stable Isotope During Postprandial Period
Measurement of L-selectin Production Rate With Stable Isotope During Postprandial Period
Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period

Full Information

First Posted
August 27, 2015
Last Updated
April 30, 2020
Sponsor
Laval University
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02536248
Brief Title
Sitagliptin Therapy and Kinetics of Inflammatory Markers
Official Title
EFFECTS OF SITAGLIPTIN THERAPY ON THE KINETICS OF MARKERS OF LOW-GRADE INFLAMMATION AND CELL ADHESION MOLECULES IN PATIENTS WITH TYPE 2 DIABETES
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
August 1, 2015 (Actual)
Primary Completion Date
September 30, 2017 (Actual)
Study Completion Date
October 31, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Laval University
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Inflammatory processes are increasingly being recognized as a critical step in the pathogenesis of both diabetes and heart disease and may constitute a biological link between the two diseases. Inflammatory cytokines increase vascular permeability, change vasoregulatory responses, increase leukocyte adhesion to endothelium, and facilitate thrombus formation by inducing procoagulant activity, inhibiting anticoagulant pathways, and impairing fibrinolysis. Leukocyte adhesion to arterial endothelial cells is thought to be an important step in the development of atherosclerosis, and adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and L-selectin, play key roles in this process. Therefore, identifying novel therapeutic approaches that would favorably affect inflammation, endothelial function, and glucose is of significant interest. Investigators have recently demonstrated that, relative to placebo, sitagliptin treatment resulted in a significant reduction in plasma levels of various inflammatory markers and cell adhesion molecules. The results also suggest that the beneficial effects of sitagliptin on both inflammation and endothelial function are most likely mediated by an elevation in plasma GLP-1 levels and global improvement of the glucose-insulin homeostasis. However, the mechanisms underlying the beneficial effects of sitagliptin on these markers remain to be fully elucidated. The proposed study will address this key issue.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
sitagliptin, diabetes, inflammation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sitagliptin first, then Placebo
Arm Type
Experimental
Arm Description
Sitagliptin 100 mg/d for 6 weeks Wash-out 14 days Placebo for 6 weeks
Arm Title
Placebo first, then Sitagliptin
Arm Type
Placebo Comparator
Arm Description
Placebo for 6 weeks Wash-out 14 days Sitagliptin 100 mg/d for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
Sitagliptin 100 mg/d for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo for 6 weeks
Primary Outcome Measure Information:
Title
Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Measurement of Serum Amyloid A Production Rate With Stable Isotope During Postprandial Period
Time Frame
6 weeks
Title
Measurement of L-selectin Production Rate With Stable Isotope During Postprandial Period
Time Frame
6 weeks
Title
Measurement of ICAM-1 Production Rate With Stable Isotope During Postprandial Period
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males 18 to 65 years of age. Post-menopausal women under age 65 on stable medical therapy for 6 months before the study (the patient should have demonstrated stable lipid panels) Women should not be on hormone replacement therapy (no recent starting or stopping) Type 2 diabetes as defined by the American Diabetes Association. Non-smoker. Body mass index between 25.0 and 40.0 kg/m2. Baseline glycated hemoglobin A1c (HbA1c) between 6.5 and 8.5%. Baseline fasting plasma glucose < 15.0 mmol/L. Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at screening and week -4. Patients having received stable doses of metformin for at least 3 months before randomization. Subjects must be willing to give written informed consent and able to adhere to dosing schedule, visit schedule and phone follow-up assessment. Patients should be otherwise generally healthy, without elevations in hepatic transaminases or abnormal renal function or coagulation. Patients having normal thyroid stimulating hormone at screening Exclusion Criteria: Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded. Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic complications will be excluded. Patients having received or being treated with insulin or a thiazolidinedione within the past 6 months will be excluded. Patients taking any other hypoglycemic agent, other than metformin. Subjects will be excluded if they have cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, significant alcohol intake etc.). Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study. Individuals with a history of mental instability, drug or alcohol abuse or individuals who have been treated or are being treated for severe psychiatric illness that, in the opinion of the investigator, may interfere with optimal participation in the study. History of alcohol or drug abuse within the past 2 years. Patients must not take alcohol during the study. Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease, that would limit study evaluation or participation. Known impairment of renal function (serum creatinine levels > 1.7 mg/dL for men), dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3 ± 1 g). Active or chronic hepatobiliary or hepatic disease. In addition, patients with aspartate aminotransferase or alanine aminotransferase >2 x upper limit of the laboratory reference range will be excluded. Subjects with coagulopathy (prothrombin time or partial thromboplastin time at Visit 1 >1.5 times control). Subjects with hemoglobin >2 x the lower limit of the laboratory reference range will be excluded. Patients who are known to have tested positive for human immunodeficiency virus (HIV). Patients who are currently enrolled in another clinical study. Patients who have used any investigational drug within 30 days of the first clinic visit. Congestive heart failure New York Heart Association (NYHA) Class III or IV. Uncontrolled cardiac arrhythmias within 3 months of study entry. Uncontrolled diabetes mellitus (HbA1c>8.5%) or other endocrine or metabolic disease known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on replacement doses of thyroid hormone are eligible for enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Couture, MD, PhD, FRCP
Organizational Affiliation
Laval University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laval University
City
Quebec City
State/Province
Quebec
ZIP/Postal Code
G1V 0A6
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Sitagliptin Therapy and Kinetics of Inflammatory Markers

We'll reach out to this number within 24 hrs